title: Distribution of free and liposome-encapsulated cefoxitin in experimental intra-abdominal sepsis in rats.
abstract: The distributions of radiolabelled free cefoxitin (FC) and liposome-encapsulated cefoxitin (LC) were compared in an animal model of intra-abdominal sepsis. Intraperitoneally administered LC was initially retained in the peritoneal cavity with subsequent preferential drug targeting to the liver (14% injected LC) and spleen (6% injected LC) by 3 h post-injection. Differing patterns of liposomal drug and lipid retention indicated that drug release from the liposome complex occurred within the peritoneum, liver and spleen. Intraperitoneal FC was rapidly taken up into the systemic circulation, with peak recovery in the blood (9% injected FC) and liver (5% injected FC) at 1 h post-injection. FC was also rapidly eliminated; 7% of the injected drug was recovered in the kidney 1 h post-injection. A negligible amount of FC was recovered in the spleen and very little FC or LC was found in the lungs of treated animals. Unlike FC, LC was found to provide a sustained bactericidal drug level (> 40 micrograms mL-1) in the peritoneal fluid for up to 5 h post-injection. LC also achieved significantly higher drug levels, compared with FC, within the liver at 3 and 5 h post-injection. Since severe intra-abdominal sepsis is often characterized by the presence of intraphagocytic bacteria in hepatic and splenic reticuloendothelial systems, the enhanced delivery of liposome-encapsulated anti-microbial agents, such as cefoxitin, to the liver and spleen may provide a more effective treatment for the septic condition.
authors.affiliation: Department of Clinical Biochemistry, Faculty of Medicine, University of Toronto, Ontario, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Kresta
authors.forename: P N
authors.initials: PN
authors.lastname: Shek
authors.forename: J
authors.initials: J
authors.lastname: Odumeru
authors.forename: J M
authors.initials: JM
authors.lastname: Bohnen
mesh_terms: D000005:Abdomen; D000818:Animals; D001424:Bacterial Infections / Q000378:metabolism*; D001442:Bacteroides Infections / Q000378:metabolism; D001441:Bacteroides fragilis; D002440:Cefoxitin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D004337:Drug Carriers; D004339:Drug Compounding; D013293:Enterococcus faecalis; D004927:Escherichia coli Infections / Q000378:metabolism; D005612:Freeze Drying; D016908:Gram-Positive Bacterial Infections / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008081:Liposomes; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D002440:Cefoxitin